Cartilage Repair: Opportunities In Motion-Preserving Orthopedics

Article preview from Start-Up - September 1, 2011

Start-ups and investors are looking to address the large and growing gap between palliative treatment and major joint surgery for patients with cartilage damage in the knee, toes and hands - although the FDA is putting up more roadblocks than ever before. In this issue we profile Articulinx, Carticept Medical and Orthox.

Cartilage Repair: Opportunities In Motion-Preserving Orthopedics

Article preview from Start-Up - September 1, 2011

The clinical and market needs for devices to address cartilage degeneration and injury while preserving motion in the knees, toes and hands earlier in the osteoarthritis (OA) disease continuum are huge and growing, driven by aging, obesity and sports injuries. The active 35 to 55 age group and baby boomer populations are in need of minimally invasive options to delay or prevent the need for major surgery. Once conservative care options are exhausted, patients would like more ways to stave off knee joint replacement, fusion in the big toe, or trapeziectomy in the basal joint of the thumb. A number of start-ups are working on innovative motion-preserving products to fill this vastly underserved void. However, the "price of admission" to this market has become very high. Getting through the FDA and into the US market is a tricky proposition indeed, and there have been casualties.

Still, brave young start-ups and select investment firms are taking the risk and banking on lucrative rewards, positioning permanent or reversible implants as functional cartilage replacements and cost savers for the overburdened US health care system. Larger players seeking acquisition targets are taking notice as well. In the next five years, a select few of the best and brightest (and most well funded) are likely to make it through the long and expensive Pre-Market Approval (PMA) pathway with viable options for relieving pain and preserving natural joint motion.

Chronic degenerative OA in the knees affects an estimated 27 million Americans aged 25 and older, and an additional two million Americans injure the cartilage in their knees each year. Debridement and microfracture are the most common treatments for cartilage defect repair, but these do not address disease progression. Also, the meniscus of the knee has in recent years been recognized as playing a crucial role in joint stability, lubrication and force transmission, and meniscal repair is one of the most commonly performed orthopedic procedures in the US.

Continued...

To read this article in its entirety, Purchase now as a PDF and receive it immediately via email. Or get it FREE when you subscribe to Start-Up.

About Start-Up

No publication reviews leading edge companies and technology better than START-UP. Each issue of START-UP profiles the most important new product companies, identifies the hottest technology areas, reviews funds flowing into private companies and investment trends, and reports on university tech transfer licensing. Industries covered: pharmaceuticals, biotechnology, medical equipment & devices, and in vitro diagnostics.

Plus:
To find out about more about more about Elsevier Business Intelligence's medical device publications and databases, multi-user access and/or advertising with Medical Devices Today, please contact Kristy Kennedy at (480) 985-9512